Biodesix, Inc. (BDSX) on Monday reported preliminary fourth quarter and full year 2025 results with revenue estimated to have increased by 41% and 22%, respectively, compared to the prior year.
Following the results, BDSX surged 31.87% to $7.21 in the pre-market trade.
Biodesix finished 2025 with estimated full-year revenue of $88.5 million, 24% higher than $71.3 million in the year ago.
This exceeds the top end of the November 3, 2025, updated revenue guidance range of $84-$86 million. However, this guidance range is below the initial guidance range of $92-95 million proposed on March 3, 2025.
For the fourth quarter, Biodesix estimated revenue increased by 41% to $28.8 million from $20.4 million in the year-ago quarter.
Lung Diagnostics' revenue is estimated at $25.2 million, up 47% from $17.2 million. The increase in Lung Diagnostics revenue was driven by growth in test volumes, higher average revenue per test, and approximately $1.0 million in collections from claims older than one year.
Development Services revenue is estimated to be $3.6 million up 13% from year ago quarter. Biodesix also affirmed positive Adjusted EBITDA compared to a loss of $3.9 million in the year-ago quarter.
BDSX closed Friday's trade at $27.55, down 1.61%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.